Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings

Page 1 of 2

Editor’s Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN), AstraZeneca plc (ADR) (NYSE:AZN)

VIVUS, Inc. (NASDAQ:VVUS)Former AstraZeneca, MedImmune exec tapped to head Vivus (FierceBiotech)
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO. Zook formerly served as executive vice president, Global Commercial Operations for AstraZeneca plc (ADR) (NYSE:AZN) and president of MedImmune. “Obesity is a growing disaster for Americans. Aside from its obvious human costs, it creates economic costs due to associated comorbidities such as diabetes, strokes, heart attacks and depression,” Zook said in a statement. “Our mission is to ensure that at-risk patients and their physicians know about Qsymia and have the information necessary to determine whether Qsymia can help address this devastating condition.”

3 Things To Watch For With Arena Pharmaceuticals (TheStreet)
When Jefferies released a research note for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) with a target price of $12, shares subsequently fell to around $6.90 since the analysis. Similar to other pharmaceutical plays, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded higher ahead of the release of weight-loss drug Belviq on the market. Obesity is a growing problem, and Belviq has a large market to address, but whether the value of the company will be driven upwards depends on a few key results. …In the near term, short sellers could dictate the depressed share price for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Short float is around 28%. Bets against Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) have risen steadily since April.

Will Amgen (AMGN) Beat Earnings? (Zacks)
Amgen, Inc. (NASDAQ:AMGN) is scheduled to report its second quarter 2013 earnings after the closing bell on Jul 30, 2013. Last quarter, Amgen, Inc. (NASDAQ:AMGN) delivered a positive earnings surprise of 11.43%. We expect the trend to continue in the second quarter. Our proven model shows that Amgen, Inc. (NASDAQ:AMGN) is likely to beat earnings because it has the right combination of two key ingredients. …The Expected Surprise Prediction or ESP, which represents the difference between the Most Accurate estimate of $1.74 and the Zacks Consensus Estimate of $1.71, is +1.75%. This is a meaningful and leading indicator of a likely positive earnings surprise for the shares.

Notable Two Hundred Day Moving Average Cross – VVUS (Forbes)
In trading on Wednesday, shares of VIVUS, Inc. (NASDAQ:VVUS) crossed below their 200 day moving average of $13.29, changing hands as low as $13.28 per share. VIVUS, Inc. (NASDAQ:VVUS) shares are currently trading down about 2.5% on the day. The chart below shows the one year performance of VIVUS, Inc. (NASDAQ:VVUS) shares, versus its 200 day moving average: Looking at the chart above, VIVUS, Inc. (NASDAQ:VVUS)’s low point in its 52 week range is $9.86 per share, with $24.86 as the 52 week high point — that compares with a last trade of $13.40.

Page 1 of 2
Loading Comments...